Our Pricing

Wegovy Maintenance Dose for Prescription Weight Loss

Published on: June 03, 2026

Understanding the wegovy maintenance dose UK prescription pathway is essential for sustained weight loss success. At Cured Pharmacy, our UK-registered clinical team supports patients through the full dose escalation schedule to the 2.4mg maintenance phase, with transparent pricing from £79.00 and ongoing prescriber guidance.

What Is the Wegovy Maintenance Dose?

The Wegovy maintenance dose is 2.4mg semaglutide administered once weekly via subcutaneous injection [1]. This represents the target therapeutic dose shown in the STEP clinical trial programme to deliver maximum weight loss efficacy whilst maintaining an acceptable side effect profile for most patients.

Patients don't begin at the maintenance dose. The MHRA-approved dose escalation schedule gradually increases from 0.25mg weekly over 16 weeks to reach the 2.4mg maintenance phase [1]. This gradual titration minimises gastrointestinal side effects such as nausea and vomiting, which are most common during initial treatment weeks.

Once you reach the 2.4mg maintenance dose, clinical guidance supports continuing this dose indefinitely, subject to ongoing prescriber review and tolerability assessment [2]. The maintenance phase is not a fixed duration—it's designed for long-term weight management rather than short-term intervention.

Wegovy Dose Escalation Schedule Explained

Your UK prescriber may adjust the escalation timeline if you experience persistent side effects. Remaining at a lower dose for an additional 4 weeks is a common clinical strategy, though this extends the time to reach maintenance. Cured Pharmacy's clinical team monitors your progress through follow-up consultations to optimise your individual pathway.

The Five-Step Titration Protocol

The UK-licensed Wegovy dose escalation follows a structured 16-week schedule: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1.0mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg maintenance [1]. Each pen is colour-coded to prevent dosing errors, and your Cured Pharmacy prescription will specify the exact dose for your current treatment phase.

Some patients experience significant weight loss before reaching maintenance dose. However, stopping escalation prematurely may limit overall efficacy. In the STEP-1 trial, patients who reached and maintained the 2.4mg dose achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [3].

How Long Should You Stay on Wegovy Maintenance Dose?

Clinical evidence supports long-term use of the Wegovy maintenance dose for sustained weight management [2]. The STEP trials followed patients for up to 104 weeks, demonstrating that weight loss is maintained whilst continuing treatment but typically rebounds after discontinuation [4].

NICE guidance recognises semaglutide 2.4mg as a long-term treatment option for adults with obesity or overweight plus weight-related comorbidities [5]. There is no predetermined stop date for the maintenance phase—your UK prescriber will review efficacy, tolerability, and ongoing clinical need at regular intervals, typically every 3-6 months.

Weight regain after stopping Wegovy is well-documented in clinical trials. In the STEP-1 withdrawal study, participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within 52 weeks [4]. This underscores that obesity is a chronic condition requiring ongoing management rather than a short-term intervention.

At Cured Pharmacy, our transparent pricing model from £79.00 per prescription supports long-term treatment planning. Your superintendent pharmacist, Tarun Kumar (GPhC 2233073), and our UK prescriber team ensure you receive consistent clinical oversight throughout your maintenance phase.

Expected Weight Loss Results at Maintenance Dose

Weight loss typically plateaus after 60-68 weeks on the maintenance dose [3]. This plateau represents a new physiological set point rather than treatment failure. Maintaining this reduced weight requires ongoing treatment, as discontinuation consistently leads to weight regain in clinical studies [4].

Clinical Trial Outcomes

The STEP-1 trial enrolled 1,961 adults with obesity or overweight plus comorbidities. At week 68, patients on Wegovy 2.4mg maintenance dose achieved a mean body weight reduction of 14.9%, compared to 2.4% with placebo [3]. Notably, 50.5% of semaglutide-treated participants lost at least 15% of their baseline body weight.

Individual results vary considerably. Factors influencing weight loss magnitude include baseline BMI, adherence to lifestyle modifications, metabolic health, and genetic factors. Your UK prescriber will assess your individual response at 3-4 months to determine whether continuing to maintenance dose is clinically appropriate.

Managing Side Effects During Maintenance Phase

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—are most common during dose escalation but typically diminish once patients reach and stabilise on the 2.4mg maintenance dose [1]. Approximately 5-10% of trial participants discontinued treatment due to adverse effects, most commonly during the escalation phase rather than maintenance.

If you experience persistent nausea at the maintenance dose, practical strategies include eating smaller meals, avoiding high-fat foods, and staying well-hydrated. Your Cured Pharmacy prescriber may recommend remaining at 1.7mg if the 2.4mg dose proves intolerable, as many patients still achieve clinically meaningful weight loss at sub-maximal doses.

Rare but serious side effects require immediate medical attention: severe abdominal pain (possible pancreatitis), visual changes, or signs of thyroid tumours. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains uncertain [1]. Your prescriber will assess your personal and family history before prescribing.

All prescription weight loss treatments available through Cured Pharmacy require ongoing clinical monitoring. Our UK-registered team provides follow-up consultations to assess tolerability, efficacy, and any emerging concerns throughout your maintenance phase.

Wegovy Maintenance Dose vs Other Weight Loss Treatments

Your choice of maintenance treatment depends on clinical factors including your weight loss target, injection frequency preference, side effect profile, and cost considerations. Cured Pharmacy offers transparent upfront pricing across all licensed weight loss treatments, with Wegovy available from £79.00 per prescription. Our UK prescribers will discuss the most appropriate option during your free online consultation, which takes under 3 minutes to complete.

Comparing Long-Term Treatment Options

Semaglutide (Wegovy) and tirzepatide (Mounjaro) represent the most effective pharmacological weight loss treatments currently licensed in the UK. Tirzepatide is a dual GIP/GLP-1 receptor agonist that demonstrated superior weight loss in head-to-head trials—approximately 22.5% body weight reduction at the highest maintenance dose compared to 14.9% with semaglutide 2.4mg [6][3].

Liraglutide (Saxenda) is an older GLP-1 receptor agonist requiring daily injections. Its lower efficacy—approximately 8% body weight reduction—makes it less suitable for patients requiring substantial weight loss, though it remains a licensed option for those who cannot tolerate weekly injections [7].

Scientific References

1. European Medicines Agency. (2021). Wegovy (semaglutide): Summary of Product Characteristics. EMA/CHMP. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
7. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy (semaglutide) is a prescription-only medicine licensed in the UK for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Side effects can occur; refer to the patient information leaflet or consult your prescriber for full safety information.